Eight Portfolio Companies of Yuansheng Venture Capital Recognized in 2025 VENTURE50
UNITED IMAGING
Artificial Intelligence Medical Product Developer
BCIFlex
Invasive High-Throughput Ultra-Thin Flexible Brain-Computer Interface System Developer
Reprogenix
Innovative Cell Therapy Developer
Ribopeutic
Small Molecule Drug Developer
Alebund
Developer of Kidney and Chronic Disease Treatment Products
XsellSmart
Stem Cell Therapy New Drug Developer
Click on the "blue words" above to follow more exciting content.
Recently, by Zero2IPO Group(1945.HK), the 2025 VENTURE50 selection results initiated by the investment community were finally announced.This year continues with the "Top 50 Rising Stars" and "Top 50 New Shoots," as well as the three major industries of artificial intelligence, hard technology, and life science. Among them, the "Top 50 Rising Stars" are unlisted companies that are in the financing stage after Series B or established before 2022, while the "Top 50 New Shoots" are unlisted companies that are in the financing stage of Series B or earlier and established after 2022. The "Top 50 in Artificial Intelligence," "Top 50 in Hard Technology," and "Top 50 in Life Science" represent high-growth companies with outstanding performance in these industries in 2025.
Eight portfolio companies of YuanSheng Venture Capital proudly made the list:
UNITED IMAGING Honored as "2025 VENTURE Top 50".
BCIFlex and OcuHealth Honored in "2025VENTURE Top 50 Emerging Companies".
BCIFlex, Haibo Pharmaceuticals, Reprogenix Bioscience, Ribopeutic, Alebund, UNITED IMAGING, Okeyhealth, and XsellSmart Honored as “2025VENTURE Investment World Life Tech 50”.
END
About YuanBio Venture Capital
YuanSheng Venture CapitalIt is an investment institution focusing on the early and growth-stage healthcare sector, based in Suzhou BioBAY with a global reach. To date, it has completed investments in over 200 outstanding enterprises in the life sciences and healthcare field, spanning four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, and future healthcare technologies. The firm has achieved substantial investment returns, with 20 portfolio companies having gone public on capital markets such as the Hong Kong Stock Exchange and STAR Market. OrbiMed China has been repeatedly recognized as one of the top 10 venture capital funds in China’s healthcare sector and one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed China possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging professionalism, dedication, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.
